Making decisions about hormone replacement therapy: Authors' reply

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7403.1398-b (Published 19 June 2003) Cite this as: BMJ 2003;326:1398
  1. Janice Rymer, senior lecturer,
  2. Ruth Wilson, professor,
  3. Karen Ballard, director of postgraduate studies
  1. Guy's, King's, and St Thomas's School of Medicine, Guy's and St Thomas's Hospital Trust, London SE1 7EH
  2. Department of Family Medicine, Queen's University, Kingston, Ontario, Canada
  3. Department of General Practice, Guy's, King's, and St Thomas's School of Medicine, King's College, London SE11 6SP

    EDITOR—Hinton et al are concerned about the administration of oestrogen to women who have had oestrogen sensitive breast cancer. In our article we suggest giving hormone replacement as add-back treatment for premenopausal women who are given gonadotrophin releasing hormone analogues and may be devastated by the hypoestrogenic symptoms that they experience as well as having significant bone loss. For reasons of space we did not specify which hormone replacement we …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription